Connect your agent to akta.pro and build company lists like this across sectors and geos.
Explore 15 biotechnology companies encountering adverse FDA regulatory actions or restrictions reported during Q3 2026. Compare application setbacks, clinical holds and their implications for product development and regulatory timelines.
— 3 Q3 rejections cite manufacturing problems — Elevar, Ultragenyx and ITM-11 had manufacturing- or facility-related FDA objections; ITM reported no clinical safety or efficacy issue.
— Several sponsors received repeat adverse FDA decisions — Elevar and Aldeyra are described as third-time rejection cases in the supporting coverage.
— Stock reactions were severe — Capricor fell 71% in July after an advisory committee voted 9 to 3 against deramiocel, Aldeyra fell about 70% on its third rejection and REGENXBIO fell about 23% on a clinical hold.
Companies ranked 1515 companies included in this ranking
Highest relevance score 5.8 of 10Lykos Therapeutics — highest scored entry
Rejections citing manufacturing issues 3 of 15Elevar Therapeutics and Ultragenyx
Coverage: United States, companies Filter: Negative sentiment Window: Jul 1, 2026 – Sep 30, 2026 Ranked by: Incident relevance Source: akta.pro News Signals Compiled: Sep 30, 2026| # | Company name | Firmographics | Funding & investors | What company does | What happened & why | Sources |
|---|---|---|---|---|---|---|
| 01 | Lykos Therapeutics lykospbc.com Elevated | Founded 2014 San Jose, CA USA | $150M Last raise 2025 | Lykos Therapeutics is a private, San Jose-based public benefit corporation developing investigational MDMA-assisted psychotherapy for post-traumatic stress disorder, currently pre-commercial following an FDA Complete Response Letter in August 2024, with two completed positive Phase 3 trials and ongoing regulatory resubmission efforts. Psychedelic-Assisted Psychiatric Therapeutics |
The FDA publicly released in August 2026 its Complete Response Letter rejecting Lykos Therapeutics' MDMA-assisted therapy for PTSD, citing safety concerns and trial design flaws. Why The letter cites inadequate documentation of abuse-related adverse events and a lack of efficacy data beyond 18 weeks, following an earlier negative advisory panel. |
3 sources · 3 outlets |
| 02 | Capricor Therapeutics capricor.com Elevated | Founded 2005 San Diego, CA USA | $330M Last raise 2025 | Capricor Therapeutics is a clinical-stage biotechnology company developing Deramiocel, an allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy, alongside a proprietary StealthX exosome delivery platform, targeting rare disease patients globally through its Nippon Shinyaku partnership. Cell Therapy Developers (Allogeneic/Off-the-shelf) |
An FDA advisory committee voted 9 to 3 against recommending approval of Capricor's deramiocel for Duchenne muscular dystrophy cardiomyopathy at its 29 July 2026 meeting, and Capricor's stock fell 71% in July after FDA briefing documents questioned the Hope-3 trial. Why The coverage cites committee concerns about the statistical stability of efficacy endpoints and whether LVEF is a validated surrogate marker. |
3 sources · 3 outlets |
| 03 | Elevar Therapeutics elevartherapeutics.com Elevated | Founded 2019 Fort Lee, NJ USA | $20M Last raise 2018 | Elevar Therapeutics is an oncology-focused pharmaceutical developer advancing cancer therapies, including rivoceranib-based treatment programs. Oncology & Hematology Pharmaceuticals |
Elevar Therapeutics and Hengrui received a third FDA Complete Response Letter, reported around 10 July 2026, for the rivoceranib and camrelizumab combination in first-line liver cancer. Why The letter cites deficiencies found in a cGMP inspection of a manufacturing site, not clinical concerns, and earlier rejections in May 2024 and March 2025 related to the same issues. |
3 sources · 3 outlets |
| 04 | Invivyd invivyd.com Elevated | Founded 2020 New Haven, CT USA | $678M Last raise 2025 | Invivyd is a clinical-stage biotechnology company developing antibody-based prevention and treatment products for infectious diseases. Monoclonal Antibody Therapeutics (mAbs) |
Invivyd received an FDA notice in July 2026 that the emergency use authorization for its COVID-19 antibody Pemgarda will end on 29 June 2027, and the FDA declined to expand the EUA for treatment in immunocompromised patients. Why The coverage says the termination follows HHS winding down COVID-19 emergency authorizations. |
3 sources · 3 outlets |
| 05 | REGENXBIO regenxbio.com Elevated | Founded 2009 Rockville, MD USA | $1.03B Last raise 2026 | REGENXBIO develops gene therapies using adeno-associated virus vector technology for rare genetic and retinal diseases. AAV Vector Gene Therapy Developers |
The FDA placed a clinical hold on REGENXBIO's RGX-121 gene therapy for Hunter syndrome on 24 August 2026, and the shares fell about 23%. Why The hold follows MRI findings of small spinal masses in five patients, which investigators call nonserious, and the company does not expect to resubmit its application soon. |
2 sources · 2 outlets |
| 06 | Sydnexis sydnexis.com Elevated | Founded 2014 Del Mar, CA USA | $50M Last raise 2021 | Sydnexis is a specialty biopharmaceutical company developing low-dose atropine ophthalmic treatments designed to slow progression of childhood myopia. Rare Ophthalmology Disorder Therapies |
The FDA issued a Complete Response Letter in mid-August 2026 for Sydnexis' SYD-101, a low-dose atropine for pediatric myopia, despite the Phase 3 STAR trial meeting its primary efficacy goals. Why The FDA found insufficient evidence of effectiveness and noted no safety or quality deficiencies. |
2 sources · 2 outlets |
| 07 | NeuroPace neuropace.com Elevated | Founded 1997 Mountain View, CA USA | $457M Last raise 2025 | NeuroPace markets the FDA-approved RNS System, a closed-loop brain-responsive neuromodulation device for adults with drug-resistant focal epilepsy. Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) |
The FDA told NeuroPace on 29 July 2026 that its premarket approval supplement to expand the RNS System to drug-resistant idiopathic generalized epilepsy was not approvable in its current form, and its shares dropped. Why The FDA is seeking additional clinical data, and the company plans a submission issue request, despite a 77% median seizure reduction in its NAUTILUS trial. |
2 sources · 2 outlets |
| 08 | Agenus agenusbio.com Elevated | Founded 1994 Lexington, MA USA | $467M Last raise 2026 | Agenus is a clinical-stage immuno-oncology company developing the BOT+BAL antibody combination (Fc-enhanced anti-CTLA-4 plus anti-PD-1) to treat immunologically cold solid tumors, currently monetizing through France's AAC compassionate access program, global Named Patient Programs, and strategic collaboration revenue ahead of Phase 3 readout in MSS metastatic colorectal cancer. Therapeutic Vaccines (e.g., Cancer/Chronic Infection) |
The FDA did not grant accelerated approval for Agenus' botensilimab and balstilimab combination, as discussed in early September 2026 coverage. Why The coverage says the FDA could not determine the individual contributions of the two drugs to the response rates. |
1 source |
| 09 | Harmony Biosciences harmonybiosciences.com Elevated | Founded 2017 Plymouth Meeting, PA USA | $1.68B Last raise 2024 | Harmony Biosciences is a publicly traded commercial-stage pharmaceutical company that develops and commercializes therapies for rare neurological disorders, led by WAKIX (pitolisant), the first FDA-approved non-scheduled treatment for narcolepsy, serving approximately 8,500 patients with 2025 revenue of $868.5 million. Rare Neurology & Neurodegenerative Disorder Therapies |
The FDA refused to file Harmony Biosciences' supplemental NDA for pitolisant in idiopathic hypersomnia, reported on 1 September 2026. Why The coverage reports the refusal to file but does not give a stated reason. |
1 source |
| 10 | Ultragenyx Pharmaceutical ultragenyx.com Elevated | Founded 2010 Novato, CA USA | $1.54B Last raise 2025 | Ultragenyx develops and commercializes therapies for rare genetic diseases, including biologics, small molecules and gene therapies. Genetic & Genomic Rare Disease Therapeutics |
The FDA issued a manufacturing-related rejection for Ultragenyx's drug UX111 in August 2026, and the shares fell about 5%. Why The company says the issue is procedural and does not reflect on clinical value. |
1 source |
| 11 | Aldeyra Therapeutics aldeyra.com Elevated | Founded 2005 Lexington, MA USA | $287M Last raise 2021 | Aldeyra Therapeutics develops therapies for immune-mediated diseases, including ophthalmic and inflammatory conditions. Immunology & Inflammation Pharmaceuticals |
Aldeyra Therapeutics received a third FDA Complete Response Letter for its dry eye drug reproxalap in early July 2026, and its shares fell about 70%. Why The coverage reports the rejection and a 50 million dollar pro forma cash position but does not detail the letter's stated reasons. |
1 source |
| 12 | ApiJect Systems apiject.com Reported | Founded 2018 Stamford, CT USA | — | ApiJect develops prefilled injectable drug-delivery and drug-device combination technologies using blow-fill-seal manufacturing processes. Medical Injection Devices & Drug Delivery |
The FDA issued a Complete Response Letter on July 21, 2026 for ApiJect Systems’ glycopyrrolate solution application (NDA 219107), declining approval in its then-current form. Why The letter raised drug-device combination product-quality and human-factors issues requiring a response before approval. |
1 source |
| 13 | Biohaven biohaven.com Reported | Founded 2013 New Haven, CT USA | — | Biohaven is a clinical-stage biopharmaceutical company developing therapies for neurological and immunological disorders, including epilepsy treatments. Neurology & CNS Biopharmaceuticals |
The FDA issued a partial clinical hold dated September 4, 2026 that paused new patient enrollment in Biohaven’s opakalim (BHV-7000) development program. Why The agency sought additional nonclinical information on a metabolite observed in rodent studies; dosing of already-enrolled patients was permitted to continue. |
1 source |
| 14 | Filana Therapeutics filanatherapeutics.com Reported | Founded 1998 Austin, TX USA | — | Filana Therapeutics is a clinical-stage biotech developing simufilam for tuberous sclerosis complex-related epilepsy. Biopharmaceutical Research & Development |
Filana reported in July 2026 that an FDA clinical hold was still preventing initiation of its planned simufilam trial. The FDA lifted that hold on September 22, 2026. Why The company worked to provide information requested by FDA; the hold was resolved during Q3. The original hold predates the July–September window. |
1 source |
| 15 | ITM USA / ITM-11 itm-radiopharma.com Elevated | Founded — Princeton, NJ (US operations) USA | — | US operations of Germany-headquartered radiopharmaceutical developer ITM, which is developing lutetium-177 edotreotide (ITM-11) for neuroendocrine tumors. Radiopharmaceutical Drug Development |
On August 7, 2026, the FDA issued a Complete Response Letter to ITM for its ITM-11 drug application, which the company disclosed on August 10. Why The FDA cited chemistry, manufacturing and controls and third-party commercial facility inspection deficiencies; the company said no clinical safety or efficacy issues were identified. The applicant is German-headquartered ITM and has a Princeton US presence. |
1 source |
This dashboard covers US biotech and specialty pharma companies in akta.pro's Healthcare & Life Sciences sector that received adverse FDA decisions in Q3 2026, including complete response letters, refusals to file, clinical holds, negative advisory committee votes and terminated authorizations. These decisions matter because a single FDA action often sets a small company's valuation and financing path.
The ranked companies include a few medical device and diagnostic sponsors, so the codes below reflect several sub-industries rather than one.
This section describes the industry classification of the ranked companies, not the Regulatory Approvals & Certifications signal category the dashboard tracks.
NAICS and SIC are global standard industry classifications, shown as returned by akta.pro Company Data for the listed companies. The internal taxonomy is akta.pro's own industry tree: each code links to its akta.pro industry page, and the signal categories this page filters on are listed in the Methodology below.